Advanced therapy market seen reaching $123 billion by 2030

The Advanced Therapy Medicinal Products market is projected to grow to $122.99 billion by 2030, driven by cell and gene therapy adoption, regenerative medicine investment, and rising demand for personalized treatments. North America is expected to remain the largest regional market, while Novartis held the top global share in 2025.

Why it matters: - Advanced therapy medicinal products are moving from niche treatments into a much larger commercial market. - The forecast points to stronger demand for cell, gene, and tissue-based therapies across cancer, rare disease, and chronic care. - The market’s growth also signals bigger opportunities in manufacturing, testing, and commercialization infrastructure.

What happened: - The Business Research Company projected the global Advanced Therapy Medicinal Products market will reach $122.99 billion by 2030. - The market is forecast to grow at a 19.1% compound annual growth rate through 2030. - The report was published in London on Oct. 27, 2026. - North America is expected to be the largest regional market in 2030, at about $45 billion. - The United States is projected to be the largest national market, at $41 billion in 2030. - Novartis AG led the global market in 2025 with a 14% share.

The details: - The market is split into somatic cell therapy medicinal products, tissue engineered medicinal products, and gene therapy medicinal products. - Somatic cell therapy medicinal products are projected to be the largest segment, at about 60% of the market, or $74 billion, by 2030. - The report also tracks gene editing technologies, viral vector technology, stem cell technology, and automation with artificial intelligence-driven processes. - Major application areas include muscular dystrophies, Alzheimer’s disease, hemophilia, and cystic fibrosis. - Hospital pharmacies and retail pharmacy outlets are the main distribution channels. - Hospitals, specialty clinics, and other healthcare providers are the key end users. - The report says cell and gene therapy adoption, regenerative medicine investment, and demand for personalized treatments are the main growth drivers. - The report estimates cell and gene therapy adoption will add about 2.3% annual growth. - Rising investment in regenerative medicine is projected to contribute about 2.2% annual growth. - Demand for personalized and rare-disease therapies is projected to contribute about 1.8% annual growth. - Combined, the fastest-growing product segments are expected to generate more than $72 billion by 2030. - Over 2025 to 2030, somatic cell therapy is forecast to add $43 billion, tissue engineered products $12 billion, and gene therapy products $17 billion. - The top 10 players accounted for roughly 30% of revenue in 2025, indicating a moderately fragmented market. - Other named companies include Gilead Lifesciences, Bristol-Myers Squibb, F. Hoffmann-La Roche, Lonza, BioMarin, Legend Biotech, AGC Biologics, UniQure, Organogenesis, Vericel, Rentschler Biopharma, JCR Pharmaceuticals, Sana Biotechnology, Fate Therapeutics, MeiraGTx, MEDIPOST, CRISPR Therapeutics, Pharmicell, Kolon TissueGene, and Adaptimmune Therapeutics. - Key raw material suppliers include Lonza, Sartorius, Thermo Fisher Scientific, Merck KGaA, Danaher, Cytiva, Corning, Bio-Rad, Charles River Laboratories, Fujifilm, Samsung Biologics, WuXi AppTec, Evotec, Repligen, Catalent, GE Healthcare Life Sciences, Takara Bio, STEMCELL Technologies, Miltenyi Biotec, Pluristem Therapeutics, and Aldevron. - Major wholesalers and distributors include McKesson, AmerisourceBergen, Cardinal Health, Medipal Holdings, Owens and Minor, Sinopharm, Shanghai Pharmaceuticals, Phoenix Pharmahandel, Zuellig Pharma, Movianto, Uniphar, H. D. Smith, Morris and Dickson, Anda, CuraScript SD, Walgreens Boots Alliance Distribution, Alliance Healthcare, Nipro Corporation Distribution Services, BioCare Medical Distribution, National Distribution and Contracting Services, Parata Systems Distribution Solutions, Biocodex Distribution Network, Theramex Distribution Services, Alloga Logistics Services, and Pharmapack Distribution Group. - Major end users include Novartis, F. Hoffmann La Roche, Pfizer, Bristol Myers Squibb, Amgen, Gilead Sciences, Biogen, AbbVie, AstraZeneca, Johnson and Johnson, Takeda, Sanofi, Bluebird Bio, Novartis Gene Therapies, Vertex Pharmaceuticals, Sarepta Therapeutics, BioMarin, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Orchard Therapeutics, Adaptimmune Therapeutics, Spark Therapeutics, Kite Pharma, and Atara Biotherapeutics. - Vertex Pharmaceuticals received FDA approval for CASGEVY in January 2024, a CRISPR Cas9-based gene editing therapy for transfusion-dependent beta thalassemia. - The therapy uses autologous stem cells with targeted editing of the BCL11A enhancer to raise fetal hemoglobin levels.

Between the lines: - The market outlook reflects a shift from experimental advanced therapies toward scaled commercial use. - North America’s lead suggests the U.S. and Canada have the clearest mix of regulatory support, clinical activity, and manufacturing capacity. - The fragmented revenue split shows no single company controls the space, even as large biopharma firms set the pace. - Gene editing stands out as the clearest near-term trend because it connects scientific breakthroughs with approved products and measurable commercial demand.

What's next: - More investment is likely in viral vector plants, cell-processing platforms, and GMP manufacturing capacity. - Partnerships between biotech firms, healthcare providers, and research institutions are expected to deepen as clinical pipelines expand. - Regulatory approvals and commercialization efforts should continue to accelerate as companies push more therapies into the market. - Artificial intelligence and automation are likely to play a larger role in development, manufacturing, and workflow optimization.

The bottom line: - Advanced therapy medicinal products are moving into a high-growth phase, with personalized cell and gene therapies driving the next wave of pharmaceutical expansion.